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Objectives: Neuropsychiatric symptoms (NPS) are very common in older patients
with dementia. There is increasing evidence that hypoperfusion of the brain plays a
role in the development of NPS. The aim of this study is to assess whether there is
an association between low systolic blood pressure (SBP) and NPS and if NPS are
more prevalent in older people with dementia using antihypertensive medication.
Methods: We studied the baseline data from participants in the Communication, Sys-
tematic pain treatment, Medication review, Organized activities and Safety study, a
multicenter clustered trial with 765 participants from 72 nursing home units from
37 nursing homes in Norway. SBP (lowest quartile vs rest) and use of antihyperten-
sive medication were predictors and Neuropsychiatric Inventory—Nursing Home ver-
sion (NPI-NH) score (total and clusters) was the outcome. Missing data were
imputed, except for missing data in predictors. We used a mixed model analysis
adjusted for age, sex and Minimal Mental State Examination (MMSE) score. In a sen-
sitivity analysis, continuous SBP values were used.
Results: In total, 412 patients were included with a mean age of 86.9 years, 53.9%
had a MMSE score of <11. There was no difference in total NPI-NH score between
low and high SBP (difference −1.07, Pdj = 0.62). There was no difference between
high and low SBP and the NPI clusters. The use of antihypertensive medication was
not associated with a different total or cluster NPI-NH score compared to no use (dif-
ference −0.99, Padj = 0.95, Pall = 0.37-0.99, respectively). In the sensitivity analyses
with the continuous SBP levels, there was no association between SBP and NPI-NH
score (estimate 1.00, 95%CI 0.98-1.01, P = 0.25).
Conclusion: We found no association between low SBP and NPS, nor between anti-
hypertensive use and NPS.
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1 | INTRODUCTION
Neuropsychiatric symptoms (NPS), such as apathy, delusions, halluci-
nations, agitation and aggressive behavior, are very common in older
people with dementia.1,2 About 90% of the people with dementia
experience at least one of these symptoms over the course of their
illness.3,4 With advanced stages of dementia in time, the severity of
NPS will change with especially a more severe degree of agitation,
depression, apathy and anxiety.5,6 NPS are highly distressing for
people with dementia and stressful for their caregivers.3,5 In addi-
tion, NPS are also known to be associated with a poorer quality of
life and increase the cost of care.7,8 The clinical management of NPS
is therefore a high priority for clinicians treating people with
dementia,3 but the efficacy and safety of the available drug treat-
ments are controversial.3,4,8,9
The etiology of NPS in dementia is multifactorial and
includes neuropathological changes in the brain as well as unmet
physical and psychological needs related to dementia.9 One of
the possible neuropathophysiological mechanisms is the
observed relationship between hypoperfusion of the brain and
NPS. There is increasing evidence that hypoperfusion of the
brain plays a role in the development of NPS like apathy,10-14
depressive symptoms,15 psychotic symptoms16 and aggressive
behavior.17 Hypertension and cardiovascular disease, such as
stroke, can cause disturbances in the cerebrovascular hemody-
namics and hypoperfusion of specific brain areas can occur
somewhere in the course of their life.18 This suggests that dis-
turbances in cerebrovascular hemodynamics followed by hypo-
perfusion of the brain may have an influence on NPS. In people
with Alzheimer's disease and vascular dementia, it is known that
they have pronounced disturbances in their cerebrovascular
hemodynamics.19 As a consequence, blood pressure reduction in
older people with impaired hemodynamic response may lead to
hypoperfusion of the brain, resulting in increased mental health
problems.20 Almost half of the nursing home residents is
affected with cardiovascular diseases21 such as hypertension and
therefore use antihypertensive medication. In people with
dementia, the use of antihypertensive medication itself has been
associated with increased occurrence of NPS22 and a greater
progression in cognitive decline.20 The underlying mechanism of
the found associations is unclear, but it is suggested that low
blood pressure may lead to hypoperfusion of certain brain areas,
that it is related to the use of the antihypertensive medication
itself, or to the cumulative damage of the cardiovascular disease
at older age.20-22
Given the above, a low systolic blood pressure (SBP) in persons
with dementia might have a negative effect on the NPS. Therefore,
we aim to assess whether there is an association between low blood
pressure and NPS in persons with dementia and if NPS are more prev-
alent in persons with dementia using antihypertensive medication
compared to persons with dementia not using antihypertensive
medication.
2 | MATERIALS AND METHODS
2.1 | Design
This cross-sectional study was performed using the baseline data from
the Communication, Systematic pain treatment, Medication review,
Organized activities and Safety (COSMOS) study.23 Full details of the
study protocol and procedures are described elsewhere.23 In brief,
data were collected between August 2014 and December 2015. In
total, 765 participants from 72 nursing home units from 37 nursing
homes in Norway were included.24 The COSMOS study is a multicen-
ter cluster randomized controlled trial that aims to improve quality of
life in nursing home residents by enhanced communication (advanced
care planning), proactive assessment and treatment of pain, discontin-
uation of unnecessary medication and organization of activities. Eligi-
ble criteria were all patients aged ≥65 years residing in long-term care
or a specialized dementia care unit without the diagnosis of schizo-
phrenia and with a life expectancy ≥ 6 months, estimated by the
treating physician. In this cross-sectional study, only participants with
cognitive impairment (Minimal Mental State Examination [MMSE]
< 24), an available blood pressure measurement and a Neuropsychiat-
ric Inventory—Nursing Home version (NPI-NH) score (partially or
complete) at baseline were included (Figure 1).
Verbal and written informed consent was obtained from the nurs-
ing home residents if they had sufficient ability to consent; if not,
written presumed consent was obtained from a legally authorized rep-
resentative, in accordance with the ethics committee requirements
and current Norwegian legislation.
2.2 | Measurements
Data collection was completed in close collaboration with a staff
member who had been familiar with the participants for a minimum of
Key points
• Neuropsychiatric symptoms are very common in older
patients with dementia and clinical management is chal-
lenging. The etiology of NPS is multifactorial.
• There is increasing evidence that hypoperfusion of the
brain plays a role in the development of neuropsychiatric
symptoms.
• No evidence was found between a low systolic blood
pressure and neuropsychiatric symptoms in this nursing
home population.
• On the contrary to earlier studies, we found no associa-
tion between neuropsychiatric symptoms and the use of
antihypertensive medication.
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4 weeks prior to data collection. The staff received training in the
appropriate use of each questionnaire and had assistance from the
researchers as needed. Baseline data per participant on socio-
demographic characteristics (age, sex and civil status) were collected
from the medical record. Cognitive performance was assessed at
baseline using the MMSE.25 The classification of the MMSE was done
on a 30-point scale where from 0 to 11 points are classified as severe
impairment, from 12 to 17 points as moderate impairment and from
18 to 23 points as mild cognitive impairment.26
2.3 | Blood pressure
The baseline blood pressure measurement was done by the nurses in
the units in mmHg according to the local procedure. SBP values were
divided into two categories, low and high SBP. Since there is no evi-
dence for the ideal blood pressure level in patients with dementia
besides the ESH/ESC guidelines target SBP >130 mmHg, nor what
the cut-off point of a low SBP would be in those patients, we defined
low SBP as a SBP <113 mmHg. This cut-off was based on the first
quartile of the SBP values at baseline.
2.4 | Use of antihypertensive medication
Scheduled drug prescriptions (excluding prescriptions given “as
needed”) were extracted from the participants' medical records.
The antihypertensive drugs were assessed by counting the num-
ber of prescriptions for drugs classified as antihypertensive medi-
cation (Anatomical Therapeutic Chemical [ATC] code C03,
C07-C09).
2.5 | Neuropsychiatric symptoms
NPS were assessed using the NPI-NH, conducted by a trained research
assistant based on a face-to face interview with the caregiver who was
familiar with the participant.27,28 Screening questions are appraised
about 12 different NPS, initially, and, when a symptom is present,
followed by questions about the frequency and severity. The frequency
is measured on a four-point scale (higher score is more frequent; score
of four points represents symptoms present on a daily basis) and sever-
ity on a three-point scale (higher score is more severe; score of three
points represents symptoms with much stress on the participant). For
F IGURE 1 Flowchart of the
study. †Nursing Home. ‡
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each of the 12 NPS, a total score was generated by multiplying the fre-
quency and severity with a maximum of 12 resulting in a maximum
total NPI-NH score of 144 points. On a test–retest reliability study, cor-
relation coefficients were 0.79 for overall frequency and 0.86 for over-
all severity. Studies have reported good inter-rater reliability.27 The
NPI-NH has been cross-validated with the NPI and is considered to be
a brief, reliable, informant-based assessment of NPS.27 The NPS were
clustered according to the four-factor model of Cheng et al.29 into the
NPI clusters psychosis, mood, behavior problems and euphoria.
2.6 | Statistical analysis
Baseline characteristics were described as mean with SD or median
with interquartile ranges (IQR) for continuous variables and as num-
bers with percentage (%) for categorical variables for all participants.
Baseline characteristics were also presented stratified for antihyper-
tensive treatment use.
In our dataset, we had 25% missing values. To deal with missing
values on the NPI-NH (8.7%), socio-demographic characteristics
(5.5%) and pulse (1.0%), these were imputed using multiple imputa-
tions, creating 20 imputation sets.30 The posterior mean matching
method was used. The following baseline variables were used to build
the imputation model: age, sex, civil status, nursing home, systolic and
diastolic blood pressure, pulse pressure, pulse, MMSE score, and the
NPI frequency and severity score. The given total NPI-NH scores and
NPI clusters scores were not included as predictors in the imputation
model to avoid instability of the model. Therefore, the total NPI score
and the NPI cluster scores were recalculated after imputation. The
NPI-NH scores were log transformed due to strong skewing of the
distribution.
First, the association between SBP (lowest quartile vs rest; pre-
dictor) and NPI-NH score (total, clusters and single symptom score) as
a measure of NPS (outcome) was assessed. Second, the association
between use of antihypertensive medication (predictor) and NPI-NH
score (total, clusters and single symptom score) as a measure of NPS
(outcome) was assessed. Linear mixed model analyses were performed
on the imputed datasets which were summarized using Rubin's rule.
To account for similarities within nursing home cluster, nursing home
cluster was included as a random effect. The model was applied in the
crude data (no adjustments) and further stepwise analyzed corrected
for age, sex and MMSE score.
In sensitivity analysis, the association between continuous SBP
values and NPI-NH scores was assessed.
Analyses were completed using SPSS version 23 (IBM, Armond,
NY, USA).
3 | RESULTS
Of the 545 participants who were assessed for their eligibility to par-
ticipate in the COSMOS study, we excluded 133 participants. Partici-
pants were excluded with a MMSE score > 23 (n = 27), missing data
on the MMSE (n = 53) or SBP levels (n = 48), or the NPI-NH was
completely absent (n = 5) (Figure 1). As a result, 412 participants were
included in this study.
Table 1 presents the characteristics of the participants. The mean
age was 86.9 (SD 7.4) year and 304 participants (73.8%) were female.
In total, 222 (53.9%) participants had a MMSE score < 11 points, indi-
cating severe cognitive impairment. The mean SBP was 128 mmHg
(SD 21.5), with a total NPI score of 10 (IQR 3-23). Antihypertensive
medication was used in 240 participants (53.3%).
When comparing, the group using antihypertensive treatment
were significantly older (P = 0.028), less females (P = 0.002) and had a
significant higher MMSE score (P = 0.025) than the nonusers of anti-
hypertensive treatment.
Table 2 shows that there was no association between total NPI-
NH score and low SBP compared to normal/high SBP (estimate 1.07,
95%CI 0.81-1.41, P = 0.65). When adjusting for age, sex and MMSE
TABLE 1 Baseline characteristics of participants overall and








Females (n,%) 304 (73.8) 167 (69.6) 137 (79.7)
Age (SD) 86.9 (7.4) 87.5 (7.2) 85.9 (7.6)
Civil status (n,%)
Married 91 (23.3) 50 (22.1) 41 (25.0)
Widow 251 (64.4) 153 (67.7) 98 (59.8)
MMSE (SD)
Total score 10.2 (6.9) 11.4 (6.6) 8.6 (7.0)
Severe <11 222 (53.9) 116 (48.3) 106 (61.6)
Moderate 12-17 116 (28.2) 74 (30.8) 42 (24.4)
Mild 18-23 74 (18.0) 50 (20.8) 24 (14.0)
Blood pressure mmHg
(SD)
Systolic 128 (21.5) 127 (20.2) 129 (23.1)














Total score 10 (3–23) 8.5 (2-20) 13 (4-28)
Psychiatric cluster 0 (0–2) 0 (0–2) 0 (0-3)
Mood cluster 4 (0-12) 2 (0-8) 3 (0-12)
Behavior cluster 2 (0–9) 4 (0–10) 6 (1-13)
Euphoria 0 (0–3) 0 (0–0) 0 (0-0)
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score, the results were similar (estimate 1.07, 95%CI 0.82-1.40,
P = 0.62; Table 3).
There was no clinically significant association between low SBP
and NPI-NH clusters, in the crude data as well as in the adjusted
model (Tables 2 and 3). Nor was there an association between low
SBP and NPI clusters when stratified for antihypertensive medication
use. Same analysis was done for all 12 single NPI items without a sig-
nificant association found (data not shown).
The use of antihypertensive treatment was associated with a
lower NPI-NH score in the crude model (estimate 1.31, 95%CI
1.02-1.68, P = 0.03, no use vs use; Table 4). On the contrary, in the
adjusted model, the association between the use of antihypertensive
treatment and the NPI-NH score diminished (estimate 1.18; 95%CI
0.92-1.51, P = 0.19; Table 5).
Separate analyses were done for the four NPI clusters. In the
crude model, the NPI cluster behavior (estimate 1.26, 95%CI
1.00-1.59, P = 0.05) and the mood cluster (estimate 1.26, 95%CI
1.01-1.58, P = 0.04) both show a significant association with the no
antihypertensive treatment group (Table 4). Conversely, no significant
association was found between use of antihypertensive drugs and the
NPI clusters in the adjusted analysis (Table 5).
In the sensitivity analyses with the continuouss SBP levels, there
was no association between SBP and NPI-NH score (estimate 1.00,
95%CI 0.98-1.01, P = 0.25).
4 | DISCUSSION
In this cross-sectional study of nursing home residents with dementia,
we did not find an association between low SBP and NPI-NH total
score, nor between the use or no use of antihypertensive medication
and the NPI-NH score.
Prior studies have identified cardiovascular disease as an impor-
tant predictor of cognitive decline.31 Moreover, fluctuations in blood
TABLE 2 Crude difference in NPI score according to systolic blood pressure (>113 mmHg vs ≤113 mmHg)
Antihypertensive treatment
Total (n = 412) Yes (n = 240) No (n = 172)
NPI-NH Estimatea (95%CI) P-values Estimatea (95%CI) P-values Estimatea (95%CI) P-values
Total NPI score 1.07 (0.81–1.41) 0.65 0.99 (0.68-1.44) 0.97 1.27 (0.83-1.95) 0.27
NPI psychosis 0.89 (0.72-1.09) 0.27 0.88 (0.66-1.15) 0.34 0.88 (0.63-1.23) 0.46
NPI behavior 0.83 (0.64-1.08) 0.16 0.43 (0.65-1.29) 0.63 0.68 (0.44-1.03) 0.07
NPI mood 0.99 (0.77-1.27) 0.93 1.10 (0.79-1.54) 0.56 0.83 (0.56-1.23) 0.36
NPI euphoria 0.93 (0.85-1.01) 0.09 0.96 (0.86-1.06) 0.40 0.89 (0.76-1.02) 0.13
Abbreviations: NPI-NH = Neuropsychiatric Inventory—Nursing Home version.
aEstimate calculated by mixed model analyses, transformed back after log transformation.
TABLE 3 Difference in NPI score according to systolic blood pressure (>113 mmHg vs ≤113 mmHg), adjusted for age, sex and MMSE score
Antihypertensive treatment
Total (n = 412) Yes (n = 240) No (n = 172)
NPI-NH Estimatea (95%CI) P-values Estimatea (95%CI) P-values Estimatea (95%CI) P-values
Total NPI score 1.07 (0.82–1.40) 0.62 0.99 (0.68-1.42) 0.95 1.32 (0.87-1.99) 0.20
NPI psychosis 1.15 (0.93-1.40) 0.19 1.13 (0.87-1.48) 0.37 1.19 (0.86-1.65) 0.29
NPI behavior 1.19 (0.92-1.54) 0.18 1.07 (0.76-1.49) 0.96 1.49 (0.97-2.25) 0.05
NPI mood 1.01 (0.79-1.30) 0.94 0.90 (0.64-1.26) 0.55 1.20 (0.81-1.77) 0.36
NPI euphoria 1.08 (1.03-1.13) 0.08 1.04 (0.99-1.09) 0.43 1.13 (0.97-1.34) 0.12
Abbreviations: MMSE = Minimal Mental State Examination; NPI-NH = Neuropsychiatric Inventory—Nursing Home version.
aEstimate calculated by mixed model analyses, transformed back after log transformation.
TABLE 4 Crude difference in NPI score according to the use of
antihypertensive medication (no use vs use)
NPI-NH Estimatea (95%CI) P-values
Total NPI score 1.31 (1.02-1.68) 0.03
NPI psychosis 1.03 (0.86-1.24) 0.73
NPI behavior 1.26 (1.00–1.59) 0.05
NPI mood 1.26 (1.01–1.58) 0.04
NPI euphoria 1.03 (0.96-1.12) 0.40
Abbreviations: NPI-NH = Neuropsychiatric Inventory—Nursing Home version.
aEstimate calculated by mixed model analyses, transformed back after log
transformation.
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pressure have been recently identified as an important risk factor for
cognitive decline. There are few studies assessing the association
between blood pressure and NPS. Evidence has been found that NPS
is related to hypoperfusion of the specific brain area's using functional
brain imagining (FBI).13 Especially apathic syndromes and aggression
are associated with hypoperfusion of specific brain areas assessed by
single photon emission computed tomography (SPECT).11,14,17 The
average MMSE score of the patient groups in these studies was much
higher compared to our study (MMSE score from 17.6 to 22 vs 10.2)
and the sample was smaller, 10 to 30 patients vs 412 patients. Blood
pressure is not taken into account in these studies. Our study used
low SBP as a hypothetic proxy variable (derivate) of hypoperfusion in
the brain, which is less accurate than FBI or SPECT, but more clinically
relevant in the nursing home setting.
A recent study found an association between the use of antihy-
pertensive medication and a higher total NPI score.22 On the contrary,
results from the crude model analysis of our study showed a signifi-
cant lower NPI cluster behavior and mood score with antihyperten-
sive treatment use. One possible explanation is the higher age and
higher MMSE score in the group using antihypertensive medication.
When adjusted for age, sex and MMSE score, there was no significant
association between antihypertensive treatment and NPI-NH score.
In line with previous studies,1,32,33 the minimal clinical important dif-
ference of the NPI total score and the NPI single symptom score is
greater than three points.29,34 This cut-off point was taken to indicate
the presence of specific “clinically relevant” symptoms. We did not
find a significant nor clinical relevant association between SBP or anti-
hypertensive treatment and the NPI score.
In the group not using antihypertensive treatment, more NPS were
found when SBP >113 mmHg (estimate 1.49, P = 0.05). This is contrary
to our hypothesis and with the previous mentioned studies.11,14
The mean SBP in our study was 128 mmHg and the 25th quartile
(113 mmHg) was used as a cut-off point. This mean SBP is assumed
to be a low average for the frail elderly. In the literature, there is no
clear or proven cut-off point for low SBP in people of old age with
comorbidities as dementia.35 Literature suggests a SBP below
120 mmHg in community-dwelling people of old age is associated
with an increased risk of cardiovascular events.35-37 It remains unclear
if this applies to the nursing home population with dementia.
Steinberg et al. assumed that a SBP below 128 mmHg and the use of
antihypertensive treatment were associated with a greater decline in
MMSE score and recommend a target SBP between 130 and
145 mmHg.20 The group that used antihypertensive treatment had on
average a higher MMSE score than the group without antihyperten-
sive treatment, on the contrary in our analyses. Since this is a cross-
sectional analysis, there was no information on cognitive decline.
A possible explanation is that physicians might be more prone to
stop the antihypertensive treatment when the MMSE is low, as for
other medications.38 Lower MMSE score, which is an indication of
more cognitive decline and more severe dementia, is associated with
NPS resulting in a higher NPI score. As a result, the use of antihyper-
tensive drugs can be associated with less NPS, without being a causal-
ity. Another possible explanation is that using antihypertensive drugs
might have a cardiovascular protective effect on the cognitive decline
at old age.
A strength of the present study is our nursing home population,
where studies in the frail and older population are scare. Research
about blood pressure and/or the use of antihypertensive drugs in
older people with dementia is scare and most of them are done in
community-dwelling elderly. Especially studies in nursing homes about
NPS and blood pressure are lacking.
Furthermore, for measurement of NPS we used the NPI-NH. It is
considered to be a brief, reliable, informant-based assessment of
NPS.27
This study has some limitations. The SBP measurement was not
standardized and extracted from the medical record.23 The blood
pressure could have been measured in different ways (lying, sitting, by
hand or automatic, on different times of the day). This was not
reported nor formally protocolized. Also, this study is done in nursing
home residence, so the results are not a good representation of the
general population. Additionally, there can be a selection bias if a par-
ticipant refused to cooperate regarding to his behavior. Furthermore,
only the use (yes/no) of antihypertensive medication was known, not
the dosage nor duration or indication. Therefore, dose—response
could not be analyzed. An association between antihypertensive med-
ication and NPI-NH score could therefore potentially be missed. In
addition, the use of psychotropic medication that could influence the
occurrence of NPS could not be taken into account on our analysis.
It remains unclear if blood pressure is associated with NPS in per-
sons with advanced dementia. The indication and duration of use of
antihypertensive medication can play a role in the association with
potential development of NPS, but even so cerebrovascular damage,
blood pressure level or the use of (a type of) antihypertensive medica-
tion itself. Further prospective research is necessary to clarify the car-
diovascular effects on the brain of persons with dementia and to have
a good understanding about the etiology of NPS and treatment
options, especially regarding blood pressure and the use of antihyper-
tensive medication.
In conclusion, we found no evidence to confirm the hypothesis
that low SBP and/or the use of antihypertensive medication are asso-
ciated with more NPS in nursing home residents with dementia.
TABLE 5 Difference in NPI score according to use of
antihypertensive medication (no use vs use) adjusted for age, sex and
MMSE score
NPI-NH Estimatea (95%CI) P-values
Total NPI score 1.18 (0.92–1.51) 0.19
NPI psychosis 1.01 (0.84-1.22) 0.88
NPI behavior 1.15 (0.91-1.46) 0.23
NPI mood 1.19 (1.06-1.49) 0.14
NPI euphoria 1.01 (0.97-1.06) 0.74
Abbreviations: MMSE =Minimal Mental State Examination; NPI-NH =Neu-
ropsychiatric Inventory—Nursing Home version.
aEstimate calculated by mixed model analyses, transformed back after log
transformation.
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Clinical Trail Registration
The COSMOS trial is approved by the Regional Committees for Medi-
cal and Health Research Ethics, 2013/1765, and registered at
clinicaltrials.gov, NCT02238652.
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